Cell Death and Disease
Q1 Journal
Open Access
Journal
Country
United Kingdom
Western Europe
Subject Area and Category
Biochemistry, Genetics and Molecular Biology
└
Cancer Research
Q1
└
Cell Biology
Q1
└
Cellular and Molecular Neuroscience
Q1
Publisher
SJR 2025
3.291
Q1
SJR Score
H-Index
202
Citations / Doc (2yr)
11.15
Total Docs. (latest)
873
Total Citations (3yr)
30,943
Publication type
Journals
ISSN
20414889
Coverage
2010-2026
Journal Rank
#620
Subject Categories
Cancer Research
Q1
Cell Biology
Q1
Cellular and Molecular Neuroscience
Q1
Immunology
Q1
Medicine (miscellaneous)
Q1
Subject Areas
Aims & Scope
Brought to you by the editorial team of Cell Death & Differentiation, Cell Death & Disease is a peer-reviewed online journal in the field of translational cell death.
It seeks to promote diverse and integrated areas of experimental and internal medicine with its specialties, including cancer, immunity and neuroscience.
It is now also accepting articles in a new area: cancer metabolism.
Cell Death & Disease seeks to encompass the breadth of translational implications of cell death, and topics of particular concentration will include, but are not limited to, the following:
Experimental medicine
Cancer
Immunity
Internal medicine
Neuroscience
Cancer metabolism
Abstracting & Indexing
Scopus
Google Scholar
Directory of Open Access Journals (DOAJ)
Web of Science
Medline
PubMed
Embase
Detailed Metrics
| Total Docs. (latest) | 873 |
| Total Docs. (3 years) | 2,709 |
| Total Refs. | 49,737 |
| Total Citations (3 years) | 30,943 |
| Citable Docs. (3 years) | 2,698 |
| Citations / Doc. (2 years) | 11.15 |
| Ref. / Doc. | 56.97 |
| % Female | 46.6% |
Metrics Visualization
Latest year data vs 3-year cumulative figures
Publication & Citation Trend
Loading trend data from Crossref...
Top 10 Most Cited Articles
Loading articles...
Researcher Reviews
Write a ReviewNo reviews yet for this journal.
Be the first to share your experience!
Share Your Experience
Your review will be published after moderation. Email will not be displayed publicly.